{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:40:46Z","timestamp":1775014846332,"version":"3.50.1"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtauto.2024.100249","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T22:30:54Z","timestamp":1722119454000},"page":"100249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9904-1727","authenticated-orcid":false,"given":"Bing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jtauto.2024.100249_bib1","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100249_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.jtauto.2024.100249_bib3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jtauto.2024.100249_bib4","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jtauto.2024.100249_bib5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijbiomac.2020.01.295","article-title":"Impact of endogenous stress on albumin structure in systemic lupus erythematosus (SLE) patients","volume":"151","author":"Arif","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"9","key":"10.1016\/j.jtauto.2024.100249_bib6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/0003-4819-112-9-682","article-title":"Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance","volume":"112","author":"Love","year":"1990","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000861","article-title":"Molecular endotypes of type 1 and type 2 SLE","volume":"10","author":"Robl","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.autrev.2010.08.014","article-title":"SLE diagnosis and treatment: when early is early","volume":"10","author":"Doria","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2024.100249_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830993","article-title":"A high prevalence of anti-EBNA1 heteroantibodies in systemic lupus erythematosus (SLE) supports anti-EBNA1 as an origin for SLE autoantibodies","volume":"13","author":"Laurynenka","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jtauto.2024.100249_bib10","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1021\/acs.jcim.1c01356","article-title":"Insights into selectin inhibitor design from endogenous isomeric ligands of SLea and SLex","volume":"61","author":"Hu","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.jtauto.2024.100249_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jclinpath-2021-207517","article-title":"Gene of the month: lymphocyte-activation gene 3 (LAG-3)","volume":"74","author":"Lythgoe","year":"2021","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100249_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3892\/ol.2020.12070","article-title":"Progress of immune checkpoint LAG-3 in immunotherapy","volume":"20","author":"Shan","year":"2020","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100249_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4049\/jimmunol.1900823","article-title":"A LAG-3-specific agonist antibody for the treatment of T cell-induced autoimmune diseases","volume":"204","author":"Angin","year":"2020","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltab025","article-title":"Seven mysteries of LAG-3: a multifaceted immune receptor of increasing complexity","volume":"2","author":"Burnell","year":"2022","journal-title":"Immunother Adv"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100249_bib16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.jtauto.2024.100249_bib17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib18","first-page":"111","article-title":"New ligand for LAG-3","volume":"20","author":"Visan","year":"2019","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100249_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/apt.17604","article-title":"Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?","volume":"58","author":"Lobat\u00f3n","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100249_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103085","article-title":"Lymphocyte activation gene-3 (LAG-3) regulatory T cells: an evolving biomarker for treatment response in autoimmune diseases","volume":"21","author":"Gertel","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100249_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.jtauto.2024.100249_bib40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.it.2003.10.001","article-title":"LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination","volume":"24","author":"Triebel","year":"2003","journal-title":"Trends Immunol."},{"issue":"10086","key":"10.1016\/j.jtauto.2024.100249_bib41","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jtauto.2024.100249_bib42","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.jid.2018.05.021","article-title":"Proportion of CD4+CD49b+LAG-3+ type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index","volume":"138","author":"Kim","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jtauto.2024.100249_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107722","article-title":"Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis","volume":"96","author":"Yu","year":"2021","journal-title":"Int. Immunopharm."},{"issue":"8","key":"10.1016\/j.jtauto.2024.100249_bib44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri2138","article-title":"Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans","volume":"7","author":"Roncarolo","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.autrev.2008.07.035","article-title":"Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept","volume":"8","author":"Fiocco","year":"2008","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100249_bib46","first-page":"5366","article-title":"Decreased regulatory T-cell frequency and interleukin-35 levels in patients with rheumatoid arthritis","volume":"16","author":"Zhang","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"9","key":"10.1016\/j.jtauto.2024.100249_bib32","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100249_bib33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4049\/jimmunol.2100850","article-title":"Fewer LAG-3+ T cells in relapsing-remitting multiple sclerosis and type 1 diabetes","volume":"208","author":"Jones","year":"2022","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100249_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0000000000000608","article-title":"LAG-3 and GAL-3 in endometrial carcinoma: emerging candidates for immunotherapy","volume":"39","author":"Friedman","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/v15010147","article-title":"LAG-3 contribution to T cell downmodulation during acute respiratory viral infections","volume":"15","author":"Rodr\u00edguez-Guilarte","year":"2023","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.jtauto.2024.100249_bib36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jtauto.2024.100249_bib20","first-page":"127","article-title":"Tim-3, lag-3, and TIGIT","volume":"410","author":"Joller","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jtauto.2024.100249_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956090","article-title":"The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application","volume":"13","author":"Huo","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib23","doi-asserted-by":"crossref","DOI":"10.1517\/14712598.2011.540563","article-title":"The CD4-like molecule LAG-3, biology and therapeutic applications","volume":"15","author":"Sierro","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.176.2.327","article-title":"Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens","volume":"176","author":"Baixeras","year":"1992","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100249_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"13","key":"10.1016\/j.jtauto.2024.100249_bib26","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100249_bib27","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100249_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105282","article-title":"Understanding LAG-3 signaling","volume":"22","author":"Chocarro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2177\/jsci.33.92","article-title":"CD4+CD25-LAG-3+ T cells in mouse and human","volume":"33","author":"Sumitomo","year":"2010","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.jtauto.2024.100249_bib30","first-page":"29","article-title":"Overview of LAG-3-expressing, IL-10-producing regulatory T cells","volume":"410","author":"Fujio","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100249_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1078-0432.CCR-22-3312","article-title":"Interferon biology and LAG-3 shedding in PD-(L)1 plus LAG-3 immunotherapy","volume":"29","author":"Karapetyan","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2249.2011.04329.x","article-title":"Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+))-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates","volume":"164","author":"Poirier","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jtauto.2024.100249_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1874312901711010113","article-title":"SLE and serum complement: causative, concomitant or coincidental?","volume":"11","author":"Sandhu","year":"2017","journal-title":"Open Rheumatol. J."},{"issue":"1\u20132","key":"10.1016\/j.jtauto.2024.100249_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0955-3886(00)00004-7","article-title":"Comparison of platelet immunity in patients with SLE and with ITP","volume":"22","author":"Lazarus","year":"2000","journal-title":"Transfus. Sci."},{"issue":"8","key":"10.1016\/j.jtauto.2024.100249_bib49","first-page":"2019","article-title":"Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999-2022","volume":"19","author":"Moe","year":"2023","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054487","article-title":"RNA-Seq for enrichment and analysis of IRF5 transcript expression in SLE","volume":"8","author":"Stone","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtauto.2024.100249_bib51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front. Med."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100249_bib52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-3083.1982.tb00737.x","article-title":"In vitro immune response of SLE lymphocytes. The mechanism involved in B-cell activation","volume":"16","author":"Takeuchi","year":"1982","journal-title":"Scand. J. Immunol."},{"issue":"7","key":"10.1016\/j.jtauto.2024.100249_bib53","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/0961203314560203","article-title":"Familial Mediterranean fever gene (MEFV) mutations and disease severity in systemic lupus erythematosus (SLE): implications for the role of the E148Q MEFV allele in inflammation","volume":"24","author":"Deniz","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jtauto.2024.100249_bib54","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2015.00550","article-title":"Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus","volume":"6","author":"Gottschalk","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2024.100249_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102376","article-title":"Treg cells in health and autoimmune diseases: new insights from single cell analysis","volume":"110","author":"Scheinecker","year":"2020","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100249_bib56","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jtauto.2024.100249_bib57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41581-022-00651-3","article-title":"Treatment of SLE with anti-CD19 CAR-T cells","volume":"18","author":"Carney","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"issue":"Suppl5","key":"10.1016\/j.jtauto.2024.100249_bib58","doi-asserted-by":"crossref","first-page":"v19","DOI":"10.1093\/rheumatology\/keaa420","article-title":"Treatment targets in SLE: remission and low disease activity state","volume":"59","author":"Golder","year":"2020","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.jtauto.2024.100249_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11071878","article-title":"LAG-3 inhibitors: novel immune checkpoint inhibitors changing the landscape of immunotherapy","volume":"11","author":"Ibrahim","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.jtauto.2024.100249_bib60","doi-asserted-by":"crossref","DOI":"10.1177\/09612033211002275","article-title":"Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus","volume":"30","author":"Yuksel","year":"2021","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ni.2180","article-title":"Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection","volume":"13","author":"Butler","year":"2011","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13045-021-01161-8","article-title":"Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target","volume":"14","author":"Qian","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.jtauto.2024.100249_bib64","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/eji.1830241246","article-title":"Lymphocyte-activation gene 3\/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes","volume":"24","author":"Huard","year":"1994","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.jtauto.2024.100249_bib65","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169598","article-title":"Aspirin and immunotherapy: a Faustian bargain?","volume":"133","author":"Goethe","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100249_bib66","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.4049\/jimmunol.180.6.3782","article-title":"Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation","volume":"180","author":"Casati","year":"2008","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.jtauto.2024.100249_bib67","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41590-022-01238-7","article-title":"LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition","volume":"23","author":"Ming","year":"2022","journal-title":"Nat. Immunol."},{"issue":"805","key":"10.1016\/j.jtauto.2024.100249_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adg2610","article-title":"The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif","volume":"16","author":"Aigner-Radakovics","year":"2023","journal-title":"Sci. Signal."},{"issue":"11","key":"10.1016\/j.jtauto.2024.100249_bib69","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41401-020-00574-4","article-title":"Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1","volume":"42","author":"Zhang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.jtauto.2024.100249_bib70","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.slasd.2023.04.003","article-title":"Development of a high-throughput TR-FRET screening assay for LAG-3\/FGL1 interaction","volume":"28","author":"Abdel-Rahman","year":"2023","journal-title":"SLAS Discov"},{"key":"10.1016\/j.jtauto.2024.100249_bib71","article-title":"The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2024.100249_bib72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fimmu.2018.00385","article-title":"Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells","volume":"9","author":"Lichtenegger","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2024.100249_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.767868","article-title":"Fibrinogen-like protein 1 serves as an anti-inflammatory agent for collagen-induced arthritis therapy in mice","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nbt0119-7","article-title":"Lupus in crisis: as failures pile up, clinicians call for new tools","volume":"37","author":"Dolgin","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.jtauto.2024.100249_bib75","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s10067-015-2994-y","article-title":"Rheumatologic emergencies","volume":"34","author":"Guti\u00e9rrez-Gonz\u00e1lez","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"51","key":"10.1016\/j.jtauto.2024.100249_bib76","first-page":"2469","article-title":"[Crisis states in systemic lupus erythematosus]","volume":"147","author":"Kiss","year":"2006","journal-title":"Orv. Hetil."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100249_bib77","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00393-022-01281-7","article-title":"[Renal manifestations in connective tissue diseases]","volume":"81","author":"Herrnstadt","year":"2022","journal-title":"Z. Rheumatol."},{"key":"10.1016\/j.jtauto.2024.100249_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978851","article-title":"MX2: identification and systematic mechanistic analysis of a novel immune-related biomarker for systemic lupus erythematosus","volume":"13","author":"Meng","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib79","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","article-title":"Metalloproteases regulate T-cell proliferation and effector function via LAG-3","volume":"26","author":"Li","year":"2007","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.jtauto.2024.100249_bib80","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.4049\/jimmunol.173.11.6806","article-title":"Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)","volume":"173","author":"Li","year":"2004","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100249_bib81","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2","article-title":"LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3\/TCR activation pathway","volume":"31","author":"Iouzalen","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.jtauto.2024.100249_bib82","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib83","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41467-018-02890-0","article-title":"IL-6\/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation","volume":"9","author":"Zhao","year":"2018","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jtauto.2024.100249_bib84","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/ecco-jcc\/jjaa054","article-title":"Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis","volume":"14","author":"Slevin","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jtauto.2024.100249_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fimmu.2016.00355","article-title":"Tr1-Like T cells - an enigmatic regulatory T cell lineage","volume":"7","author":"White","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2024.100249_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100157","article-title":"Usefulness of the hemogram as a measure of clinical and serological activity in systemic lupus erythematosus","volume":"5","author":"Moreno-Torres","year":"2022","journal-title":"J Transl Autoimmun"},{"issue":"Suppl 1","key":"10.1016\/j.jtauto.2024.100249_bib87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00393-021-01051-x","article-title":"Polyautoimmunity in systemic lupus erythematosus: secondary Sjogren syndrome","volume":"82","author":"Sieiro Santos","year":"2023","journal-title":"Z. Rheumatol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib88","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/BOR.0000000000000922","article-title":"An update on autoantibodies in systemic lupus erythematosus","volume":"35","author":"G\u00f3mez-Ba\u00f1uelos","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jtauto.2024.100249_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/flupu.2023.1234578","article-title":"Modeling of horizontal pleiotropy identifies possible causal gene expression in systemic lupus erythematosus","volume":"1","author":"Chepelev","year":"2023","journal-title":"Front Lupus."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12866-022-02533-x","article-title":"Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients","volume":"22","author":"Li","year":"2022","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.jtauto.2024.100249_bib91","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2020\/e1450","article-title":"Relationship between neutrophil-to-lymphocyte ratio and systemic lupus erythematosus: a meta-analysis","volume":"75","author":"Wang","year":"2020","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000418","article-title":"Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells","volume":"7","author":"Russell","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jtauto.2024.100249_bib93","article-title":"Clinical landscape of LAG-3-targeted therapy","volume":"14","author":"Chocarro","year":"2022","journal-title":"Immunooncol Technol"},{"issue":"9","key":"10.1016\/j.jtauto.2024.100249_bib94","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J. Immunol."},{"issue":"7710","key":"10.1016\/j.jtauto.2024.100249_bib95","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in T cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jtauto.2024.100249_bib96","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/eji.200526090","article-title":"Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells","volume":"35","author":"Kisielow","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jtauto.2024.100249_bib97","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.2147\/JIR.S378953","article-title":"Fibrinogen-like protein 1 as a novel biomarker of psoriasis severity","volume":"15","author":"Sun","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"5","key":"10.1016\/j.jtauto.2024.100249_bib98","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cpt.2091","article-title":"Depletion of LAG-3+ T cells translated to pharmacology and improvement in psoriasis disease activity: a phase I randomized study of mAb GSK2831781","volume":"109","author":"Ellis","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jtauto.2024.100249_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.579228","article-title":"Fibrinogen-like protein 1 is a novel biomarker for predicting disease activity and prognosis of rheumatoid arthritis","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.jtauto.2024.100249_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104484","article-title":"Lymphocyte Activation Gene-3 (LAG-3) negatively regulates environmentally-induced autoimmunity","volume":"9","author":"Jha","year":"2014","journal-title":"PLoS One"},{"issue":"5260","key":"10.1016\/j.jtauto.2024.100249_bib101","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1126\/science.272.5260.405","article-title":"Independent modes of natural killing distinguished in mice lacking Lag3","volume":"272","author":"Miyazaki","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib102","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jtauto.2024.100249_bib103","article-title":"Engineered small extracellular vesicles as a FGL1\/PD-L1 dual-targeting delivery system for alleviating immune rejection","volume":"9","author":"Tsai","year":"2022","journal-title":"Adv. Sci."},{"issue":"8","key":"10.1016\/j.jtauto.2024.100249_bib104","doi-asserted-by":"crossref","first-page":"R435","DOI":"10.1016\/j.cub.2018.01.059","article-title":"Exosomes and ectosomes in intercellular communication","volume":"28","author":"Meldolesi","year":"2018","journal-title":"Curr. Biol."},{"issue":"7","key":"10.1016\/j.jtauto.2024.100249_bib105","doi-asserted-by":"crossref","first-page":"7959","DOI":"10.1021\/acsnano.9b09065","article-title":"Engineering programmed death ligand-1\/cytotoxic T-lymphocyte-associated antigen-4 dual-targeting nanovesicles for immunosuppressive therapy in transplantation","volume":"14","author":"Xu","year":"2020","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.jtauto.2024.100249_bib106","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1172\/JCI81131","article-title":"Regulation of chronic inflammatory and immune processes by extracellular vesicles","volume":"126","author":"Robbins","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jtauto.2024.100249_bib107","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1943180","article-title":"PD-L1\/LAG-3 bispecific antibody enhances tumor-specific immunity","volume":"10","author":"Jiang","year":"2021","journal-title":"OncoImmunology"},{"issue":"11","key":"10.1016\/j.jtauto.2024.100249_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112826","article-title":"The role of TIM-3 and LAG-3 in the microenvironment and immunotherapy of ovarian cancer","volume":"10","author":"Koz\u0142owski","year":"2022","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100249_bib109","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/imt-2022-0185","article-title":"Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?","volume":"15","author":"Abi-Aad","year":"2023","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.jtauto.2024.100249_bib110","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1111\/jth.15345","article-title":"FGL1 as a modulator of plasma D-dimer levels: exome-wide marker analysis of plasma tPA, PAI-1, and D-dimer","volume":"19","author":"Thibord","year":"2021","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.jtauto.2024.100249_bib111","article-title":"The hepatokine FGL1 regulates hepcidin and iron metabolism during the recovery from hemorrhage-induced anemia in mice","author":"Sardo","year":"2023","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.jtauto.2024.100249_bib112","first-page":"697","article-title":"Loss of FGL1 induces epithelial-mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma","volume":"55","author":"Bie","year":"2019","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib113","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jtauto.2024.100249_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.07.007","article-title":"LAG3+ regulatory T cells restrain interleukin-23-Producing CX3CR1+ gut-resident macrophages during group 3 innate lymphoid cell-driven colitis","volume":"49","author":"Bauch\u00e9","year":"2018","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.jtauto.2024.100249_bib115","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.4049\/jimmunol.1100714","article-title":"Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3","volume":"187","author":"Bettini","year":"2011","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.jtauto.2024.100249_bib116","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909024000194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909024000194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:10:04Z","timestamp":1730898604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909024000194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":116,"alternative-id":["S2589909024000194"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2024.100249","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2024.100249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100249"}}